BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Covington
McKesson
Accenture
Chubb
Harvard Business School
Cantor Fitzgerald
Express Scripts
Dow

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,130,208

« Back to Dashboard

Which drugs does patent 6,130,208 protect, and when does it expire?

Patent 6,130,208 protects KENGREAL and is included in one NDA.

This patent has forty-one patent family members in thirty-four countries.
Summary for Patent: 6,130,208
Title: Formulation containing a nucleotide analogue
Abstract:A pharmaceutical composition comprising a nucleotide analogue and one or more glass forming additives which is suitable for freeze drying.
Inventor(s): Broadhead; Joanne (Loughborough, GB)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:09/125,165
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Process;

Drugs Protected by US Patent 6,130,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTIONTO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,130,208

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9702680Jul 11, 1997
PCT Information
PCT FiledJune 29, 1998PCT Application Number:PCT/SE98/01287
PCT Publication Date:January 21, 1999PCT Publication Number: WO99/02542

International Patents Family Members for US Patent 6,130,208

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2216330 ➤ Subscribe
Portugal 1000079 ➤ Subscribe
Poland 192768 ➤ Subscribe
Poland 337970 ➤ Subscribe
New Zealand 502073 ➤ Subscribe
Norway 329918 ➤ Subscribe
Norway 20000123 ➤ Subscribe
Malaysia 116421 ➤ Subscribe
South Korea 100786654 ➤ Subscribe
South Korea 20010021647 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Merck
US Army
Medtronic
Cantor Fitzgerald
Chinese Patent Office
Covington
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot